Text Size

Use of Fish Oils to Reduce the Frequency and Duration of Episodes of Atrial Fibrillation in Patients With Paroxysmal Atrial Fibrillation.

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2005 by Melbourne Health.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Melbourne Health
ClinicalTrials.gov Identifier:
NCT00232245
First received: October 2, 2005
Last updated: NA
Last verified: October 2005
History: No changes posted
  Purpose

The purpose of this study is to investigate whether fish oil supplements may reduce the frequency and duration of paroxysmal atrial fibrillation episodes.

Atrial fibrillation is a heart condition which effects a large percentage of the population .

Atrial fibrillation is a condition frequently experienced by people who have had pacemakers inserted .

Certain Pacemakers have sophisticated monitoring features that are able to recognise episodes of atrial fibrillation.

Fish oil supplements may be of benefit to patients with heart problems.Recent evidence suggests that fish oils may be beneficial to patients with rhythm disturbances.

By interrogating pacemakers this study will investigate the effect of fish oil supplements on the frequency and duration of episodes of atrial fibrillation.


Condition Intervention
Atrial Fibrillation
 Drug: Fish oil

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment

Resource links provided by NLM:

Drug Information available for: Fish oil
U.S. FDA Resources

Further study details as provided by Melbourne Health:

Estimated Enrollment: 60
Study Start Date: December 2003
  Eligibility

Ages Eligible for Study:   18 Years to 88 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Patients who have had at least 2 previous episodes of atrial fibrillation and an implanted pacemaker.

Exclusion Criteria:

  • Patients with chronic atrial fibrillation
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00232245

Contacts
Contact: Paul Sparks, MBBS,PhD, FRACP 0393427000 ext 27133 paul.sparks@mh.org.au

Locations
Australia, Victoria
Royal Melbourne hospital Recruiting
Melbourne, Victoria, Australia, 3050
Contact: Paul Sparks, MBBS,PhD,FRACP     93427000 ext 27133     paul.sparks@mh.org.au    
Contact: Fiona Sutherland     93427000 ext 27133     fiona.sutherland@mh.org.au    
Sponsors and Collaborators
Melbourne Health
Investigators
Principal Investigator: Paul Sparks Melbourne Health
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00232245     History of Changes
Other Study ID Numbers: 2003.216
Study First Received: October 2, 2005
Last Updated: October 2, 2005
Health Authority: Australia: Department of Health and Ageing Therapeutic Goods Administration

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on May 23, 2013